Ventracor Administrators Favor Sale To U.S.-based Siqro
This article was originally published in PharmAsia News
Administrators of Australia's Ventracor, a maker of medical devices, have recommended the company's creditors support selling the company rather than accepting a shareholder solution. U.S.-based Siqro has offered to buy Ventracor's assets and the administrators said that was the better offer. Siqro wants to market Ventracor's VentrAssist heart pump in the United States, and the administrators feel its offer would give creditors full payment of what they are owed. A shareholder group promotes raising funds to make the purchase possible, but administrators questioned the availability of post-sale funds. (Click here for more
You may also be interested in...
Demand for tele-diagnostic tools has reached unprecedented levels during COVID-19, said Kees Wesdrop, Royal Philips’ chief business leader of precision diagnosis.
Transparency On COVID Vaccine Clinical Holds Needed, Sharfstein Says; US FDA Advisory Cmtes Offer Venue
Former acting Commissioner Josh Sharfstein argues that while agency officials have done a commendable job in overall communication on COVID vaccine development, more information is needed on the clinical holds.
Trump administration effort to reduce drug prices by curtailing agency program requiring new approvals for some old products undermines FDA’s role in policing the safety of prescription drugs, experts say.